Everyday trade-offsPoster · 16 of 28
Everyday umbrella
You wouldn’t settle for this.
Easy to open is only one thing you expect from an umbrella. Convenience is also only part of choosing a screening test. In the FDA-reviewed study, about 57% of people with advanced precancer tested negative with Cologuard Plus in one screening round.
The evidence behind it
The full caption
You wouldn’t settle for this.
Easy to open is only one thing you expect from an umbrella. When choosing a screening test, convenience is also only part of the decision. Know what your test can miss.
In the FDA analysis, 1,113 of 1,962 people with advanced precancer tested negative with Cologuard Plus—56.7%, or about 57%, in one screening round. This is not a cancer miss rate or the percentage of negative results containing advanced precancer.
Colonoscopy can find and remove detected precancerous polyps. It can also miss lesions and involves preparation, logistical burdens and procedural risks. Stool DNA testing is a legitimate at-home option that requires repeat screening; a positive result needs follow-up colonoscopy. A negative stool result does not automatically mean an immediate colonoscopy is needed.
Colonoscopy First advocates high-quality colonoscopy for screening-eligible, average-risk adults who are medically appropriate, willing and have timely access. Ask your clinician about the tradeoffs and choose a screening plan you can complete.
Study sponsored by Exact Sciences, maker of Cologuard Plus. One-round performance does not establish lifetime screening outcomes. The scenes are AI-generated visual analogies, not clinical evidence. The catalog listings and prices are fictional and do not represent screening-test prices.